

Row
A
B
C
Lesion 1
Lesion 2
Lesion 3
Edema
Lesion 1
Lesion 2
Lesion 3
Edema
Lesion 1
Lesion 2
Lesion 3
Edema

Figure 1



Lesion 1
Lesion 2
+Gado
T2
+Gado
T2
Row
A
B
C
D
Baseline
Baseline
Pre-C2 (pre-dex)
Pre-C2 (pre-dex)
Mid-C4 (Off-Study)
Mid-C4 (Off-Study)
s/p anti-VEGF +VPS
s/p anti-VEGF +VPS

Figure 2A



Lesion 3
Lesion 4
+Gado
T2
+Gado
T2
Row
A
B
C
D
Baseline
Baseline
Pre-C2 (pre-dex)
Pre-C2 (pre-dex)
Mid-C4 (Off-Study)
Mid-C4 (Off-Study)
s/p anti-VEGF +VPS
s/p anti-VEGF +VPS

Figure 2B



Lesion 5
+Gado
T2
Row
Baseline
A
Pre-C2
(pre-dex)
B
Mid-C4
Off-Study)
C
Status Post
anti-VEGF
+VPS
D

Figure 2C




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7



Anti-B7-H3 Antibody Clinical Trial
Patient sB7-H3
sB7-H3 (ng/mL)
40
30
20
10
0
C1 D1
C1 D22
C1 D36
C1 D50
C2 D1
Early Termination
End of Tx

Figure 8



Anti-B7-H3 Antibody Clinical Trial
Glioblastoma Patient sB7-H3
sB7-H3 (ng/mL)
30
20
10
0
C1 D1
C1 D22
C1 D29M
C1 D36
C1 D50
C3 D1
End of Tx

Figure 9